, respectively) from 10 individuals with chronic HIV infection who were receiving ART (mean duration, 8.8 years; range, 2.7-15). We used cell-staining reagents and gating techniques that matched those used by Descours et al. 1 (see Supplementary Methods and Extended Data Fig. 1 ). As shown in Fig. 1a , we detected no enrichment for HIV DNA in the CD32 hi or CD32 int CD4 T cells. Moreover, the CD32 hi and CD32 int subsets combined accounted for no more than 3% of all HIV DNA copies within circulating CD4 T cells in any of the 10 study participants (Fig. 1b) . Post-sort flow cytometry of CD32 hi and CD32 int populations showed heterogeneous patterns that suggested the formation of T cell-B cell or T cell-monocyte conjugates as the origin of most CD32 hi or CD32 int CD4 T cells, with separation of these conjugates during sorting (Extended Data Fig. 2 ).
To rule out the possibility that we had inadvertently obtained false negative results either by excluding HIV-infected, CD32
+ CD4 T cells using tight light scatter gates or by failing to exclude non-T-cell contaminants, we performed parallel sorts on the same 10 samples using an alternative gating scheme. We used a more inclusive light scatter gate as well as markers for B cells, monocytes, dendritic cells and natural killer cells (Extended Data Fig. 3 ). Events that were CD3 + were separated into fractions that were positive for B cell markers (T-B), positive for one or more other non-CD4-T-cell markers (T-other), or negative for all of these, positive for CD4, and CD32 hi , CD32 int or CD32 lo . Neither CD32 hi nor CD32 int CD4 T cells were enriched for HIV DNA (Fig. 2a) . Similarly, we detected no enrichment for HIV DNA in the T-B and T-other populations (Fig. 2a) . In each of the 10 participants, at least 96% of all HIV DNA copies occurred in conventional CD32 lo cells (Fig. 2b ). Post-sort flow cytometry suggested that most events bearing both T-cell and non-CD4-T-cell markers again represented cell-cell conjugates, and also showed that most remaining CD32 hi CD4 T cells did not reproducibly show a high CD32 signal after sorting (Extended Data Fig. 4 ). This was in contrast to conventional CD32 lo cells, which were uniformly pure in post-sort analyses across participants. In a second group of four individuals whose peripheral blood mononuclear cells (PBMCs) were sorted without previous cryopreservation (Extended Data Fig. 5a ), we again found no enrichment for HIV DNA based on CD32 expression (Extended Data Fig. 5b ), and also observed that HIV DNA sequences in CD32 + CD4 T cells were genetically intermingled with HIV DNA sequences in other CD4 T cells (Extended Data Fig. 5c ).
Overall, our studies showed no enrichment for HIV DNA in CD32 + CD4 T cells, and also raised questions about the source of the CD32 labelling on these cells. We propose that the CD32 expression associated previously with CD4 T cells could have arisen from adherent non-T-cells or cellular material bearing this marker, and that conjugates containing HIV-infected CD4 T cells could be differentially produced and/or recovered in different laboratories with different sample processing and FACS practices. It is important to acknowledge that these considerations do not explain the discrepancy between the Descours et al. study 1 and ours in the quantities of HIV DNA detected within CD3
+ sorted material. Nevertheless, we wish to emphasize that our findings do not support targeting CD32 molecules on CD4 T cells in emerging HIV cure strategies.
Methods
Participant recruitment and informed consent were performed under Institutional Review Board (IRB)-approved protocols at the US National Institutes of Health (NIH). For FACS, whole PBMCs were stained with monoclonal antibodies matching those used by Descours et al. 1 (see Supplementary Methods) and sorted on a BD FACSAria. To evaluate purity, a portion of each population was re-analysed on the flow cytometer after sorting. Virus DNA copies in sorted cells were enumerated by fluorescence-assisted clonal amplification 2 . DNA recovery was quantified by albumin (ALB) quantitative PCR. Because the FUN-2 monoclonal antibody used + and bearing markers of B cells (T-B; upper gate, fourth column) or other non-CD4-T-cells (T-other; combined ungated events from fifth and sixth columns) were also collected in separate tubes. + cells that did not show high CD4 expression after sorting.
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Post-sort analyses of CD3 + CD4 + CD32 hi populations were deferred in cases in which these populations were too small to permit both post-sort analysis and downstream HIV DNA quantification (that is, donors # 1, 4 and 6-8). , and singlecopy HIV DNA sequence analysis from CD32  hi , CD32  int and CD32   lo   CD4 T cell populations, and from T cells also bearing non-CD4-T-cell markers. a, PBMCs from four additional study participants were collected from whole blood by venipuncture with immediate processing (without cryopreservation). The T-other population was collected as a combination of the ungated events from CD19/CD20, CD16/CD14 and γδ T cell receptor/CD123 exclusion plots (fourth, fifth and sixth columns). b, Left, copies of HIV DNA per million cells sorted from four additional study participants as in a. Right, percentages of all HIV DNA copies detected in blood cells deriving from CD32 hi , CD32 int , CD32 lo and T-other subsets, calculated by adjusting values in the left panel for the relative proportions of these subsets determined using FACS data. c, Sequences of individual HIV DNA copies were determined by Sanger sequencing of products obtained by fluorescence-assisted clonal amplification, which amplifies a region of the HIV env gene. Phylogenetic trees were constructed as described in the Supplementary Methods. All Bonferroni-corrected Slatkin-Maddison P values for genetic compartmentalization between any two subsets were greater than 0.05 in all four participants. e 1 6 | n a t u r e | V o L 5 6 1 | 2 0 s e P t e m B e r 2 0 1 8 A group of study participants was selected to match roughly the size of the study in which the finding we wished to investigate was initially reported.

Data exclusions
Describe any data exclusions. None
Replication
Describe whether the experimental findings were reliably reproduced.
All data acquired are reported, and so the reproducibility of the finding can be judged within the publication.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No randomization was performed.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section) Describe the software used to analyze the data in this study.
One extended data figure legend reports negative results from Slatkin-Maddison testing for genetic compartmentalization between groups of DNA sequences. This testing was performed using HyPhy, which is deposited in GitHub. The reference for this software is included in the Supplemental Methods.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No restrictions.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Antibodies used for flow cytometry were purchased from commercial suppliers and had been validated for use in human samples and published previously. Details of these reagents are included in the Supplemental Methods. 
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
None
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
Human research subject participants were recruited from IRB-approval intramural NIH research protocols. All human research participants had chronic HIV infection with a history of successful treatment on antiretroviral therapy (ART). 
Data presentation
For all flow cytometry data, confirm that:
1. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
2. The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
3. All plots are contour plots with outliers or pseudocolor plots. FACSDiva was used for data collection. Analysis was performed in FlowJo.
8. Describe the abundance of the relevant cell populations within post-sort fractions.
Post-sort analyses of some cell populations were >98% pure, but post-sort analyses of other populations were not pure. This fact -that some sorted populations are not what they appear to be on first pass through the flow cytometer -is a key part of the argument in the manuscript.
9. Describe the gating strategy used. All samples were initially gated using forward scatter and side scatter to identify events corresponding to cells, and then using forward scatter height vs. area to enrich for single cells. Cell populations thus gated were further gated as shown in Extended Data Figures 1, 3 , and 5. The entirety of the gating for all of the samples studied is presented in the Extended Data (not in the Supplement; the ticked box below indicates that the data are included in the submission).
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information. The persistence of latent HIV-1 in resting memory CD4 + T cells is a major barrier to a cure, and a biomarker for latently infected cells would be of great scientific and clinical importance [1] [2] [3] [4] [5] . Using an elegant discovery-based approach, Descours et al. 6 reported that CD32a, an Fcγ receptor not normally expressed on T cells, is a potential biomarker for the HIV-1 reservoir in CD4 + T cells 6 . Using a quantitative viral outgrowth assay (qVOA), we show that CD32 +
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CD4
+ T cells do not contain the majority of intact proviruses in the latent reservoir and that the enrichment found by Descours et al. 6 may in part reflect the use of an ultrasensitive ELISA that does not predict exponential viral outgrowth. Our studies show that CD32 is not a biomarker for the major population of latently infected CD4 + T cells. There is a Reply to this Comment by Descours, B. et al. Nature 561, https://doi.org/10.1038/ s41586-018-0496-1 (2018).
If CD32a is a biomarker for latent HIV-1 infection in CD4 + T cells, one that is never expressed on CD4 + T cells in the absence of HIV-1 infection, then a difference in the frequency of CD4 + T cells that express CD32 in HIV-1-infected individuals relative to the frequency in healthy donors is expected. We isolated CD4 + T cells from infected and uninfected donors by negative selection and analysed the expression of CD32 and CD4 by flow cytometry. In healthy donors, an average of 0.019% of CD4 + T cells was also CD32 + (Fig. 1a ). This value is not significantly different from levels in HIV-1-infected individuals ( Fig. 1a ; average 0.011%, P = 0.1143) or from values previously reported by Descours et al. 6 in HIV-1-infected individuals (0.016%, P = 0.66). Thus, CD32 does not seem to be a specific biomarker of latently infected CD4 + T cells. To examine whether replication-competent proviruses were present in CD4 +
CD32
hi T cells, total CD4 + T cells were isolated by negative selection from six HIV-1 + individuals that were treated with suppressive anti-retroviral therapy (ART) for at least 6 months (Supplementary Table 1 ). Freshly isolated cells were stained and sorted to obtain CD4 +
hi and CD4 + CD32 − populations, which were analysed in qVOAs 7 ( Fig. 1b, protocol 1 ). The number of CD4 + CD32 hi cells assayed for each subject is shown in Fig. 1c . On day 14, outgrowth was measured using a standard ELISA for the HIV-1 p24 antigen. CD4
wells from all subjects were negative for p24 on day 14, and remained negative after an additional week of culture. Conversely, outgrowth was observed in CD4 +
− wells from all subjects on both days 14 and 21. The mean infected cell frequency, 1.37 infectious units per million cells (IUPM), was comparable to values previously measured in resting CD4 + T cells in several studies (0.03-3.00 IUPM in HIV-1-infected patients 8 , 0.97 IUPM in chronically infected patients 9 ) and to values previously measured in the same subjects (mean value 1.33 IUPM) (Fig. 1d, Supplementary Table 2 ). If the enrichment of proviruses in CD32 + cells reported by Descours et al. 6 was characteristic of replication-competent proviruses, then outgrowth from CD4 +
hi T cells should have been seen (Fig. 1e) .
One possible explanation for the discrepancy between our results and those of Descours et al. 6 is that some latent HIV-1 may be present in a previously undescribed population of CD4 + T cells that express CD32 together with other non-T-cell lineage markers. Such cells would be removed during the negative selection used to isolate CD4 + T cells. Therefore, we freshly isolated total CD4
+ cells from infected donors on suppressive ART using two methods: negative selection to remove other lineages, leaving untouched CD4 + T cells, and positive selection for cells expressing CD4 (Fig. 1b, protocol 2 ). Both CD4 + populations were analysed by qVOA. No significant differences were observed in the frequencies of latently infected cells (Fig. 1f) . Furthermore, no significant differences in proviral DNA were observed between the purified cell populations (Fig. 1g) . Because CD4 is required for HIV-1 entry into the host cell, cell populations obtained via positive selection for CD4 should include every latently infected CD4 + T cell. Given that neither the infected cell frequencies nor the levels of proviral DNA differed between the purified cell populations, we conclude that no additional sizable population of latently infected cells was recovered by positive CD4 selection.
In further studies, we used a cell sorting strategy identical to that of Descours et al. 6 on samples freshly isolated from six subjects receiving ART treatment. Peripheral blood mononuclear cells (PBMCs) isolated from subjects were stained and sorted to obtain CD3 Table 3 . In addition, total CD4 + cells were obtained by staining PBMCs for CD4 and sorting for CD4
+ cells (Fig. 1b, protocol 3) . qVOA results showed that both the CD3 + CD4 + CD32 − and the total CD4 + T cell populations had the same infected cell frequencies that were comparable to frequencies measured in other studies 10 . However, we observed no outgrowth in CD3
hi cultures (Fig. 1h , Supplementary Table 2) .
We also analysed CD3 + CD4 + CD32 hi and CD3 + CD4 + CD32 − cells isolated by the method of Descours et al. 6 for the presence of proviral DNA by qPCR. We found 89 copies of gag per million CD3
− cells, which is similar to previous measurements in total CD4 + T cells 11 . However, no proviral DNA was detected after DNA extraction from 39,000 CD3
hi cells and subsequent qPCR analysis (data not shown). This finding makes it highly unlikely that this cell population is enriched for HIV-1 to a level of more than one provirus copy per cell, as reported by Descours et al. 6 . We caution that the normalization of very low-level HIV-1 DNA measurements from qPCR reactions done with a low number of input cells could artificially produce apparent enrichments in HIV-1 DNA.
In a further attempt to explain the discordant qVOA results obtained in our studies and those of Descours et al. 6 , we tested whether the use of the ultra-sensitive p24 digital ELISA 12 and the low cell input can affect IUPM calculations, leading to erroneous overestimation of latent infection. qVOA culture supernatants were assayed for HIV-1 p24 using the ultrasensitive SIMOA p24 2.0 assay (Quanterix) on days 5, 9, 14 and 21. Using the lower limit of quantification (0.01 pg ml ) as the cut-off level, we found that two out of three qVOAs containing CD4 + CD32 hi cells tested positive for p24 by this assay, even though the same wells were negative by standard ELISA, which is several orders of magnitude less sensitive (Fig. 2a) . Exponential outgrowth is the hallmark of replication-competent viruses. In qVOA cultures of CD4 +
− cells, only a fraction of the wells that were positive by SIMOA showed exponential outgrowth as determined by standard ELISA on day 21 (Fig. 2b) . Importantly, CD4
hi culture wells that tested positive by SIMOA p24 assay showed no exponential outgrowth and had significantly lower levels of p24 (Fig. 2c) . It is possible that low positive SIMOA values could reflect an assay artefact or the presence of defective proviruses that are still capable of producing low levels of Gag 13 . A further concern 2 0 s e P t e m B e r 2 0 1 8 | V o L 5 6 1 | n a t u r e | e 1 7
is that the IUPM calculations are based on cell input, fold dilutions and technical replicates 14 , and thus, qVOA analyses performed with very small numbers of sorted CD4 + CD32 hi cells can markedly skew the frequency of cells harbouring replication-competent proviruses (fivefold dilutions from 800 to 1 cell in Descours et al. 6 ). When we applied the results obtained with the SIMOA p24 assay, IUPM values ranged from 0 to 3,134 and 554 (patients 4 and 5, respectively; Fig. 2d ). As a consequence, when we calculated the 'fold enrichment' of IUPM in the CD4
hi cells compared to the CD4 + CD32 − cells, we observed a mean fold enrichment of 665 (range 152-1179, from the two patients with positive p24 using SIMOA), similar to what was reported by Descours et al. 6 ( Fig. 2e ). In summary, we find no evidence that CD32 expression indicates the presence of latent HIV-1, and demonstrate that at least a substantial fraction of the HIV-1 latent reservoir is in CD3
+ CD4 + CD32 
− T cells. The use of an ultrasensitive p24 ELISA assay may account for the apparent enrichment observed in culture experiments by Descours et al. 6 . In short, our results have demonstrated that CD32 does not define the HIV-1 reservoir and that future research is needed to identify biomarkers for latently infected cells.
We thank the study participants without whom this research would not be possible. 
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Methods qVOAs isolated CD4
+ T cells using negative depletion and were sorted for CD32 + cells (Fig. 1b, protocol 1) . To test whether negative depletion was causing a loss of CD32 + CD4 + T cells, outgrowth and proviral DNA were compared from qVOAs in which CD4 + T cells were isolated using positive selection to measurements using negative depletion. Outgrowth measurements and proviral DNA were also measured using the methods described by Descours et al. 6 . Proviral DNA measurements were performed using qPCR 15 . HIV-1 p24 values were measured using both a standard ELISA for p24 antigen (Perkin Elmer) and SIMOA (Quanterix). Further details are provided in Supplementary Methods. Data availability. All data are available from the corresponding author upon reasonable request. Competing interests Declared none.
Additional information Supplementary information accompanies this Comment.
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Experimental design 1. Sample size
Describe how sample size was determined.
Sample size for the viral outgrowth experiments was increased from 6 to 12 at the request of the reviewers. In 12 of 12 patients studied by viral outgrowth assays on sorted cells, normal outgrowth was observed in populations lacking CD32+ cells and no outgrowth was found from CD32+ cells.
Data exclusions
Describe any data exclusions.
No data were excluded from the manuscript.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Each cell isolation protocol was repeated six times in order to ensure reproducibility.
Randomization
Randomization was not relevant to this study. Participants were chosen based on having an undetectable plasma HIV-1 RNA (< 50copies/ml) level for greater than 6 months.
Blinding
Blinding was not relevant to this study because no bias could be made by the subject or the tester in the experiments performed.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
n/a Confirmed
The statistical test(s) used and whether they are one-or two-sided Describe the software used to analyze the data in this study.
Infectious units per million were calculated using the infection frequency calculator, which can be found at: http://silicianolab.johnshopkins.edu.
Materials and reagents
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
No unique material was used and all materials can be obtained from a standard commercial source.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). No commonly misidentified cells lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide all relevant details on animals and/or animal-derived materials used in the study.
No animals were used.
Description of human research participants
All HIV-1 infected research participants that were included in this study had undetectable plasma HIV-1 RNA (< 50copies/ml) for greater than 6 months.
Corresponding author(s): Robert Siliciano
Flow Cytometry Reporting Summary Form fields will expand as needed. Please do not leave fields blank.
Data presentation
3. All plots are contour plots with outliers or pseudocolor plots. 
Methodological details
5. Describe the sample preparation.
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using density centrifugation on a Ficoll-Hypaque gradient.
6. Identify the instrument used for data collection.
Flow cytometry for healthy donor and HIV-infected donor CD32 frequency analysis was performed using the iQue Screener Plus (Intellicyt Corporation). Cell populations used in quantitative viral outgrowth assays were sorted using either a SH800 cell sorter (Sony Biotechnology) or a Beckman Coulter MoFlo Cell Sorter.
7. Describe the software used to collect and analyze the flow cytometry data.
Sort data was analyzed using the Summit software version 4.3 from Beckman Coulter.
Purity was determined by running a purity check of the sorted populations after the sort was completed. CD32-fractions had a purity of greater than 98% for each sort that was completed.
9. Describe the gating strategy used.
Preliminary gates were set to collect viable lymphocytes and singlets. Then the specific sorted population gates were based on the isotype controls.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information. A recent report by Descours et al. 1 suggests that the cell surface expression of the low affinity Fc receptor CD32a (also known as FcγRIIa) marks the replication-competent HIV-1 reservoir in CD4 + T cells from 12 HIV-1-infected participants receiving suppressive anti-retroviral therapy (ART) 1 . We have undertaken considerable efforts to replicate these findings using peripheral blood mononuclear cells (PBMCs) from 20 HIV-1-infected, ART-suppressed participants (Extended Data Table 1 ). We found no evidence to suggest that CD32a marks a CD4
Brief CommuniCations arising
+ T cell population enriched in either HIV-1 DNA or replication-competent HIV-1 in our study participants. There is a Reply to this Comment by Descours, B. et al. Nature 561, https://doi.org/10.1038/ s41586-s41586-018-0496-1 (2018).
To validate these findings, we adopted the same gating strategy as described by Descours et al. 1 to define CD4 + T cell populations ( Supplementary Fig. 1a ). The CD32 antigen was identified using the same antibody clone (FUN-2) as described by Descours et al. 1 . We observed the same CD4 + T cell subsets that stained at a high cell surface density of CD32 (CD4 + CD32 high ), an intermediate cell surface density of CD32 (CD4 + CD32 int ), and a CD4 + T cell subset lacking CD32 expression (CD4 + CD32 neg ). We obtained frequencies of CD4
+
CD32
high T cells that ranged from 0.002% to 0.026%, with a median value (0.012%) that was identical to that reported by Descours et al. 1 (Extended Data Table 2 and Supplementary Fig. 1a) . Notably, we confirmed that this same CD4
+
CD32
high population is also present in PBMCs isolated from eight healthy donors and exists at similar frequencies to that in HIV-1-infected samples (P = 0.971, Extended Data Fig. 1a) .
Next, we assessed the amount of replication-competent HIV-1 isolated from the same 20 participants by measuring the infectious unit per million cells (IUPM) in CD4 + T cells (range 0.01-37.5, median 0.46). Participant CD4 +
high T cell populations were colour-coded in descending order, and then divided into quartiles that corresponded to the relative frequency of CD4
high cells present in these samples (Fig. 1a) .
After cytometric sorting of the various CD4 + CD32 subsets, we quantified HIV-1 DNA in each population (total CD4 + , CD4 + CD32 neg , CD4
int and CD4 Fig. 1b ) using droplet digital PCR (ddPCR), as described in the Methods. We found no evidence of HIV-1 DNA enrichment in the CD4 +
high fraction. We observed no significant difference in HIV-1 DNA between any populations and the CD4 +
high T cell population (P = 0.28). In fact, levels of HIV-1 DNA in the CD4 +
high T cell subsets isolated from nine participants was at the assay limit of detection (Fig. 1b) . After correction for cell input in the CD4 + CD32 high fraction, as estimated DNA values, we saw no evidence for HIV-1 DNA enrichment (open symbols in Extended Data Fig. 1b) .
We then compared the relative frequency of the CD4 + CD32 high T cell populations and the viral replicative capacity (IUPM values) per participant, but no relationship between the two parameters was observed (Fig. 1c) . All values have been tabulated in Extended Data Table 2 .
The HIV-1 reservoir largely resides in quiescent CD4 + T cells 2, 3 . Therefore, we sought to confirm the activation status of the CD4 + T cell populations by measuring the frequency of the activation markers CD69, CD25 and HLA-DR on CD4
+ T cell subsets from all participants. We found that the CD4 + CD32 high T cells were highly activated compared to the CD4 + CD32 neg T cells (P < 0.0001). Notably, among the activation markers, HLA-DR was particularly enriched, 
neg cell populations (median 1.4%) (Extended Data Fig. 1c , P < 0.0001).
Two CD32 isoforms (CD32a and CD32b) are known to be expressed among all antigen presenting cells (APCs), but not typically on T cells. Therefore, we sought to exclude any APCs as potential contaminants of flow cytometry sorting. We evaluated the co-expression of lineage markers for all major CD32-bearing cells including monocytes, B cells, dendritic cells, granulocytes and natural killer cells. As expected, all CD32
+ T cells expressed high amounts of CD3 and CD4 (Fig. 1d) . However, we found that most CD4 + CD32 high T cells from HIV-1 + patients, and also from healthy donors, co-expressed several B cell markers including CD19, CD40 and HLA-DR (Fig. 1d , e, Extended Data Fig. 2a) . Notably, the B cell antigens found on CD4 + CD32 high T cells were present at similar cell-surface densities as detected on bona fide B cells (Fig. 1d, e, Extended Data Fig. 2a) .
The demonstration that the CD4 + CD32 high fraction seen in HIV-1 + patients was marked with several B cell antigens and was similarly present in naive donors led us to investigate the origin of these B cell markers on a CD4 + T cell. Several reports have shown that B cells exclusively express the CD32b isoform 4 . The FUN-2 antibody clone used by Descours et al. 1 cannot distinguish between the CD32a and CD32b isoforms. Therefore, we used the monoclonal antibody clone 2B6 that has been reported to exclusively bind to CD32b 4, 5 . After co-staining PBMCs from HIV-1 + and HIV-1 − individuals with both the FUN-2 and the 2B6 antibodies, we found that all CD4 +
high T cells were marked only by the CD32b isoform and not by CD32a (Fig. 1d, e , Extended Data Fig. 2b ), indicating that B cells are the origin of the CD32b antigen that marks the CD4
high T cells. We sought to confirm this by determining whether CD32A (also known as FCGR2A) or CD32B (FCGR2B) mRNA was endogenously produced in the CD4 +
high subsets. After isolating total cellular RNA from various sorted T cell subsets, we used established reverse transcription PCR (RT-PCR) primers and probes that are specific to the CD32a and CD32b isoforms, as described in the Methods. We found that sorted CD4 +
high T cells from four HIV-1-infected participants did not contain detectable levels of the CD32A isoform. However, the CD32B mRNA isoform was readily detected in CD4 +
high T cells isolated from two out of four HIV-1 + patients (Extended Data  Fig. 2c ). By additional RT-PCR analysis, we detected both CD3G and CD19 transcripts in the same CD4 +
high T population, indicating that the CD32b marking the CD4 +
high T cells may be from B cells expressing cognate CD32b (Extended Data Fig. 2d ).
Because this may require cell-to-cell interaction, we performed a back-gating analysis of our flow cytometry data and confirmed that all CD4
+
CD32
high populations were identified within single-cell gates (Supplementary Fig. 1b) 
high populations had both a significantly higher FSC-A (P < 0.0001) and SSC-A (P < 0.0001), suggesting that the CD4 + CD32 high population may consist largely of cell doublets (Fig. 1f, g ).
We 
high fraction contained a high frequency of cell doublets (mean value 94%) (Extended Data Fig. 3 ). Of these 'doublets' , approximately 70% seemed to be coincident doublets, and 30% were conjugates of T and B cells (Fig. 2a and Extended Data Fig. 3b) .
We observed no examples in which CD32 staining on T cells was distributed throughout the cell membrane, supporting the idea that the CD32 found in the CD4 +
high population is not the result of endogenous expression from CD4 + T cells. Of the instances in which CD32 was detected on a T cell in the CD4 +
high population, the staining was punctate and often co-localized with punctate CD19 staining (Fig. 2b) , suggesting that CD32 was acquired via contact between B and T cells. We noted that the frequency of T cells with punctate CD32 staining was substantially higher in the sorted CD32 int population. Thus, sorting for CD4 + T cells with a 'high' surface density of CD32 results in the selective enrichment of contaminating T-B cell doublets. As shown in Supplementary Fig. 1 , these doublets cannot be discerned by routine cytometric FSC and SSC singlet gating strategies.
In summary, using samples from 20 HIV-1-infected, ART-suppressed participants, our data contradict the assertion that CD32a is a marker of , we found no difference in the total HIV-1 DNA content between CD4 + T cell populations including or excluding the CD32 high fractions (Fig. 1b) . Notably, the CD4 + CD32 high population was highly activated. Previous studies that have evaluated CD32 expression on T cells suggest that it may be detected after activation 6, 7 and led us to believe that this population may be atypical compared to a quiescent population harbouring the HIV-1 reservoir 2, 3 . Our additional findings are incongruent with CD32a marking the replication-competent reservoir in CD4 + T cells; our phenotyping and RT-PCR experiments indicate that it is the CD32b isoform that marks the CD4 +
high cells (Fig. 1d , e, Extended Data Fig. 2b-d ). This finding, combined with the demonstration that this cell population is found in uninfected individuals, conflicts with the assertion of Descours et al. 1 that CD32a is upregulated after the establishment of viral latency. Recent reports have corroborated the absence of CD32a transcripts in reactivated, clonal HIV-1-infected CD4 + T cells 8 . The surface density of CD32b (and other B cell markers) on the CD4 +
high population was observed at similar densities to that on B cells. These data, combined with the post-hoc analysis, suggests that this population may be largely comprised of doublets. Direct interrogation of the CD4 +
high population via Amnis imaging confirmed that this population consisted largely of contaminating doublets; either co-incident events or cell-to-cell conjugates (Fig. 2a) .
We demonstrate that the mechanism by which the CD32b isoform labels the CD4 
int population (Fig. 2b) . This may explain the transfer or membrane painting of antigens such as CD32b, CD40 and HLA-DR, among other markers [9] [10] [11] . Not only have cell-tocell membrane transfers been shown to occur commonly in vivo during viral infections, but such transfers largely occur on activated cells 
int population support this notion (Fig. 2a, b) . Collectively, our findings confirm that selectively sorting for T cells with a high surface density of CD32 results in the enrichment of T-B cell doublet contaminants, which cannot be discerned by routine gating strategies. The true isoform, CD32b, that marks the CD4 + CD32 high population is probably indicative of dynamic CD4
+ T cell interaction with B cells, rather than a marker of the HIV-1 reservoir 14, 15 . We thank S. Mordecai for Amnis technical expertise, and acknowledge support from NIAID grants AI091514, AI122942, AI127089 and AI131365 awarded to J.B.W. Support was also provided by the NIAID awarded Martin Delaney Collaboratory 'BELIEVE' grant AI126617, co-funded by NIDA, NIMH and NINDS awarded to D.F.N.
Methods
HIV-1
+ participants were recruited through: The Maple Leaf Medical clinic in Toronto, Canada; The HIV Eradication and Latency (HEAL) cohort of Brigham and Women's and Massachusetts General Hospital; The Whitmann Walker Clinic in Washington, DC; or the Hospital of the University of Pennsylvania. The study was approved by the University of Toronto, The University of Pennsylvania and George Washington University ethics committees and according to the protocol approved by the Partners Human Research Committee and Institutional Review Board (IRB). Written informed consent was obtained from each participant.
The percentage of CD32 + (clone FUN-2) CD4 + T cells was measured in samples from study participants. Both CD32 + and CD32 neg CD4 + T cells were sorted and viral DNA was measured using ddPCR. The analysis of cell lineage markers by flow cytometry and RT-PCR was also conducted. Flow cytometry sorts from PBMCs used in HIV-1 DNA analyses were performed on cell subsets and assessed using Amnis imaging flow cytometry. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
We used either Graphpad Prism (version 7) or STATA (version 14). For flow cytometry analyses, we used FlowJo (version 9.9.6). For flow imaging analysis we used IDEAS (version 6.2)
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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